Ganirelix
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
250 mcg
Compound profile
Ganirelix scientific & efficacy data
Hormone Support
Peptide profile
Strong human trials
Ganirelix
250 mcg · Once daily
Molecular formula
C80H113ClN18O13
- Mol. weight
- 1570.4 g/mol
- CAS number
- 124904-93-4
- PubChem
- 16186314
- Developed · 1995
- Organon/Schering-Plough Research Team
Organon (later Schering-Plough)
Amino acid sequence
Ac-D-Nal(2)-D-Phe(4-Cl)-D-Pal(3)-Ser-Tyr-D-hArg(Et2)-Leu-hArg(Et2)-Pro-D-Ala-NH2Ovulation Control
Allows doctors to control exactly when ovulation happens
IVF Success Improvement
Improves success rates in IVF cycles
Safety & OHSS Prevention
Prevents premature LH surge that can ruin egg quality
Dosing
How much Ganirelix do I take?
250 mcg · once daily during the mid-to-late follicular phase
250 mcg
Once daily during the mid-to-late follicular phase
Covers timing · dose-adjustment guidance.
Suitability
Is Ganirelix right for me?
Best for improving ivf or icsi success rates & preventing premature ovulation during egg retrieval cycles
Best for
Improving IVF or ICSI success rates
Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature ovulation during egg retrieval cycles
Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Controlling ovarian stimulation in women with unpredictable cycles
Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Ganirelix with similar peptides to find the best fit for your goals.
Administration
How do I use Ganirelix?
Subcutaneous injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is Ganirelix safe?
7 common side effects · 2 serious
Ganirelix is an FDA-approved GnRH antagonist whose safety was evaluated in 794 women in two controlled clinical trials, with treatment lasting 1–14 days.
[4] Adverse events were infrequent: gynecological abdominal pain 4.8%, headache 3.0%, ovarian hyperstimulation syndrome 2.4%, vaginal bleeding 1.8%, and injection site reactions and nausea 1.1% each.
[4] Hypersensitivity reactions, including anaphylaxis, angioedema and urticaria, have been reported after marketing, sometimes with the first dose; the needle shield on some syringes contains natural rubber latex.
[4] Because it blocks the GnRH receptor directly, it causes no initial release of gonadotropins. [4]
Efficacy rests on two trials: a double-blind dose-finding study in 332 women, in which 250 mcg gave the best pregnancy rate (35.7% per attempt, against 6.7–13.6% at 500–2000 mcg), and an open-label study in 463 women, in whom a premature LH surge occurred in under 1%.
[4] In the controlled trials, 11.9% had a neutrophil count of at least 8.3 × 10⁹/L, and hematocrit and total bilirubin shifted downward; the label says the clinical significance was not determined.
[4] An observational study of more than 1,000 newborns found congenital anomaly rates comparable to GnRH agonist cycles. [4]
Common side effects · experienced by some users
Mild discomfort at treatment site
Some users experience mild discomfort, which is among the most commonly reported effects with Ganirelix. This typically resolves within a few days as the body adjusts.
Management: Apply ice if needed. Rotate treatment sites. These symptoms typically improve within the first week of use.
Injection site reactions (redness, bruising, swelling)
Injection site reactions were reported in 1.1% of women in the label's controlled trials. [4] Redness, bruising or mild swelling can occur with repeated daily injections and typically does not require stopping treatment.
Management: Rotate injection sites daily between abdomen and thighs. Apply ice immediately after injection to reduce bruising. Avoid injecting in bruised areas. Use proper subcutaneous technique to minimize tissue trauma. Pain relief medication is rarely needed but available if desired.
Headaches
Headache was reported in 3.0% of women in the label's controlled trials. [4] It is usually mild and may also reflect the hormonal changes of ovarian stimulation.
Management: Stay well hydrated throughout the stimulation cycle, aiming for 2-3 liters of water daily. Apply cool compresses to forehead or back of neck. Rest in a quiet, dark room if headache is bothersome. Acetaminophen or ibuprofen is safe to use (check with your clinic). Headaches usually improve on their own.
Abdominal pain
Gynecological abdominal pain was the most common adverse event in the label's controlled trials, at 4.8%; gastrointestinal abdominal pain was 1.0%. [4] Much of it reflects ovarian enlargement from FSH stimulation. Pain that suddenly worsens can signal ovarian hyperstimulation syndrome (2.4% in the trials). [4]
Management: Heat application (heating pad on low setting for 15-20 minutes) often provides relief. Wear comfortable, loose clothing. Avoid strenuous exercise and intercourse. Gentle walking is fine. Over-the-counter pain relievers are usually adequate. Contact your clinic if pain suddenly worsens or is severe, as this could indicate ovarian hyperstimulation.
Pelvic discomfort
A sense of pelvic heaviness or fullness comes mainly from ovarian enlargement during FSH stimulation. The label's controlled trials list gynecological abdominal pain at 4.8% and no separate pelvic-discomfort figure. [4]
Management: Rest when possible. Wear supportive, loose-fitting clothing. Avoid heavy lifting and strenuous activity. Warm baths may ease discomfort. Stay hydrated. Pelvic discomfort is expected and not dangerous unless accompanied by severe pain, which requires immediate clinic contact.
Nausea
Nausea was reported in 1.1% of women in the label's controlled trials. [4] It is usually mild and resolves without stopping treatment.
Management: Eat small, frequent meals rather than three large ones. Avoid greasy, fried, or strong-smelling foods. Ginger candies or ginger tea can help settle nausea. Stay hydrated with clear fluids. Take anti-nausea medication only if approved by your clinic, as some medications affect egg quality. Nausea usually resolves spontaneously.
Fatigue or dizziness
Fatigue and dizziness are not among the adverse events reported in at least 1% of women in the label's controlled trials. [4] When they occur during a cycle they are more often linked to stimulation, sleep or hydration.
Management: Prioritize adequate sleep and rest, aiming for 7-8 hours nightly. Rise slowly from lying or sitting positions to prevent orthostatic dizziness. Stay well hydrated. Avoid excessive heat (hot showers, saunas). Moderate, gentle exercise like walking may help maintain energy. Report persistent severe dizziness to your clinic immediately.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Ganirelix
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Ganirelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:FSH (follicle-stimulating hormone) for egg growth — May be used together under medical guidance.
- Safe:hCG (human chorionic gonadotropin) to trigger final egg maturation — May be used together under medical guidance.
- Safe:GnRH agonists in certain protocol variations — May be used together under medical guidance.
With medications
- Caution:Other GnRH antagonists (like cetrorelix) in the same cycle — Use with caution—discuss with your healthcare provider.
- Caution:Certain herbal supplements that affect hormones — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Ganirelix. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know Ganirelix is working?
Strong human trials · first signs day 1-4
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved for this use
Onset of effects
Moderate
(1-2 weeks)
How it works
Ganirelix works like a lock that prevents the key (GnRH) from opening the door to egg release.
Unlike agonists that initially stimulate before shutting down, ganirelix immediately blocks the GnRH receptors, preventing the LH surge that triggers ovulation. During IVF, this gives doctors precise control over when eggs mature and can be retrieved, dramatically improving success rates.
The deeper mechanism
Ganirelix is a synthetic decapeptide derived from native GnRH with amino acid substitutions at positions 1, 2, 3, 6, 8 and 10.
[4] It competitively blocks GnRH receptors on the pituitary gonadotroph, producing a rapid, reversible suppression of gonadotropin secretion that is stronger for LH than for FSH, without the initial gonadotropin release seen with GnRH agonists.
[4] During controlled ovarian stimulation it is given once daily under the skin from the mid-to-late follicular phase until the day of the hCG trigger, preventing a premature LH surge.
[4] Peak levels are reached about 1 hour after injection, absolute bioavailability is 91.1%, and the half-life is about 13 hours after one dose and 16 hours at steady state, which is reached after 3 days. [4]
What to expect
Day 1-4
What you might notice
- Start FSH injections to stimulate egg growth
- Not yet started
What's normal
- Initial response to Ganirelix is beginning at the cellular level
- Different individuals experience Ganirelix's onset at different rates
- Transient systemic effects from initial Ganirelix exposure are common
What's next
- Maintain consistent Ganirelix administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Day 5-6
What you might notice
- When leading follicle reaches 14mm, start daily ganirelix injections
- Begin 250 mcg once daily
What's normal
- Ganirelix is achieving sufficient receptor engagement
- Initial mechanism of Ganirelix is taking effect
- Early transient effects from Ganirelix administration are resolving
What's next
- Maintain consistent Ganirelix administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Day 7-12
What you might notice
- Continue both FSH and ganirelix, with frequent monitoring via ultrasound
- Continue same dose unless adjusted by doctor
What's normal
- Ganirelix is achieving sufficient receptor engagement
- Initial mechanism of Ganirelix is taking effect
- Early transient effects from Ganirelix administration are resolving
What's next
- Maintain consistent Ganirelix administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Day 10-14
What you might notice
- When 2-3 follicles reach 18mm, receive hCG trigger shot to finalize egg maturation
- Take final dose same evening as trigger
What's normal
- Ganirelix is achieving sufficient receptor engagement
- Initial mechanism of Ganirelix is taking effect
- Early transient effects from Ganirelix administration are resolving
What's next
- Maintain consistent Ganirelix administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Day 11-15
What you might notice
- Egg retrieval procedure 34-36 hours after hCG trigger
- Stopped - cycle complete
What's normal
- Ganirelix response patterns are emerging
- Initial Ganirelix response is consistent with mechanism expectations
- Early tolerance development to Ganirelix is not expected
What's next
- Assess whether Ganirelix response aligns with expectations
- Plan next steps based on initial Ganirelix tolerance and response
- Establish baseline monitoring for Ganirelix response tracking
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Ganirelix over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Ganirelix tested in people
97 registered studies, 9 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 15,296 people took part in the studies that actually administered Ganirelix. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?
ART Fertility Clinics LLC
IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols
Hanoi Medical University
hCG Priming in Women With Diminished Ovarian Reserve
Kristine Loessl
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Ganirelix is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked about Ganirelix
How fast does ganirelix work?
Ganirelix starts suppressing LH levels within 1-2 hours of injection. Full suppression is achieved within 24 hours, making it much faster than GnRH agonists that can take 2-3 weeks to work.
Why is blocking LH so important for IVF?
Your body naturally releases eggs on its own schedule through an LH surge. In IVF, doctors need to control the timing to retrieve mature eggs. Without ganirelix, the LH surge would release eggs before they're optimally mature, ruining the cycle. Ganirelix gives doctors complete control.
How is ganirelix different from cetrorelix?
Both are GnRH antagonists, but studies show cetrorelix may provide slightly better LH suppression and lower OHSS risk, while ganirelix works equally well for most patients and may be faster-acting for some. Your doctor chooses based on your situation.
Are the injections painful?
Most patients describe them as relatively painless since they're small needles used for subcutaneous (under the skin) injection. However, repeated injections can cause bruising. Rotating sites and using ice can minimize discomfort.
Can ganirelix affect pregnancy if I'm already pregnant?
Ganirelix should NOT be used if you're pregnant or suspect you are. Always do a pregnancy test before starting a new IVF cycle. If you become pregnant during treatment, stop immediately and contact your doctor.
What happens if I miss a dose?
Take the missed dose as soon as you remember, unless it's almost time for your next dose. Missing a single dose might allow an LH surge, potentially compromising that cycle. Call your fertility clinic immediately if you miss a dose.
Can I use ganirelix at home?
Yes! Ganirelix comes in a pre-filled syringe that's easy to self-inject at home. Most patients inject into the abdomen or thigh. Your fertility clinic will teach you the technique before your cycle starts.
How many eggs does ganirelix help retrieve?
Ganirelix doesn't determine egg quantity - FSH does that. Ganirelix's job is preventing premature ovulation so those eggs can be retrieved when ready. Studies show it helps increase the percentage of mature eggs (which improves quality).
Further reading
Ganirelix history & related research
History · since 1999
The hormone brake for baby-making breakthroughs
A small protein hormone that stops the body from releasing eggs too early during fertility treatment. It gives doctors perfect timing control for IVF.
Read the full history of GanirelixReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Ganirelix, on one page.